Efficacy and Tolerability of Cyclobenzaprine Extended Release for Acute Muscle Spasm: A Pooled Analysis (Q39282006)

10 September 2017

Efficacy and tolerability of cyclobenzaprine extended release for acute muscle spasm: a pooled analysis (English)

1 reference

10 September 2017

Efficacy and Tolerability of Cyclobenzaprine Extended Release for Acute Muscle Spasm: A Pooled Analysis (English)

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

14 June 2024

author name string

Srinivas Nalamachu

3

1 reference

10 September 2017

Fang Xie

5

1 reference

10 September 2017

Arnold J. Weil

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20675978

14 June 2024

Gary E. Ruoff

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20675978

14 June 2024

Charles A. Altman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20675978

14 June 2024

Donald R. Taylor

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20675978

14 June 2024

language of work or name

English

0 references

publication date

1 July 2010

1 reference

full work available at URL

10 September 2017

http://www.tandfonline.com/doi/pdf/10.3810/pgm.2010.07.2182

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

14 June 2024

published in

Postgraduate Medicine

1 reference

10 September 2017

122

1 reference

10 September 2017

4

1 reference

10 September 2017

158-169

1 reference

Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials

10 September 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Cyclobenzaprine and back pain: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Epidemiological features of chronic low-back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

The Saskatchewan Health and Back Pain Survey. The prevalence of neck pain and related disability in Saskatchewan adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Low back pain research priorities: a survey of primary care practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Low back pain: an economic assessment in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

The economic burden of low back pain: a review of studies published between 1996 and 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Back pain prevalence and visit rates: estimates from U.S. national surveys, 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage therapy, and spinal manipulation for back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Cyclobenzaprine in Intractable Pain Syndromes With Muscle Spasm

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

21 January 2018

Adherence to Medication

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

A pharmacokinetic comparison of single doses of once-daily cyclobenzaprine extended-release 15 mg and 30 mg: a randomized, double-blind, two-period crossover study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Effect of food on the pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg: a randomized, open-label, crossover, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults : a randomized, open-label, two-period crossover, single-centre study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

The association between clinical findings on physical examination and self-reported severity in back pain. Results of a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Correlation of patient and caregiver ratings of cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

A systematic review of the associations between dose regimens and medication compliance

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Non-compliance--or how many aunts has Matilda?

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.07.2182

Physician office visits for low back pain. Frequency, clinical evaluation, and treatment patterns from a U.S. national survey

21 January 2018

8

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

Seven chronic conditions: their impact on US adults' activity levels and use of medical services

14 June 2024

12

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

14 June 2024

Clinical Therapeutics

17

1

409

Nibbelink DW

1978

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

14 June 2024

Clinical Therapeutics

26

10

216

Katz WA

1988

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

14 June 2024

Clinical Therapeutics

29

6

592

Greenberg RN

1984

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

Cyclobenzaprine ER for muscle spasm associated with low back and neck pain: two randomized, double-blind, placebo-controlled studies of identical design

14 June 2024

36

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups

14 June 2024

38

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

Intertester reliability for selected clinical tests of the sacroiliac joint

14 June 2024

42

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

Normality and reliability in the clinical assessment of backache

14 June 2024

43

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

The effect of prescribed daily dose frequency on patient medication compliance

14 June 2024

46

1 reference

https://api.crossref.org/works/10.3810/PGM.2010.07.2182

14 June 2024

Identifiers

1 reference

10 September 2017

1 reference